A year of ups and downs in Ridgeway: is it still the hope of the people?

category:Finance
 A year of ups and downs in Ridgeway: is it still the hope of the people?


In novel coronavirus pneumonia conference held in October 16th, the director general of the World Health Organization, Tan desse, said that in the mid-term results of the United trial, the results of Reeds trial, hydroxychloroquine, LP and Tonave and interferon therapy seemed to have little effect on the 28 day mortality or hospitalization duration of the patients.

The WHO trial showed that radcivir almost did not work in severe cases, 301 of 2743 severe patients in the radcivir group died, 303 out of 2708 severe patients in the control group died; the mortality rates were 11% and 11.2% respectively, and the death rate curves of radcivir and the control group during the 28 day trial period were highly coincident, with almost no significant difference.

But before the results of the solidarity test came out, Gilead had submitted it for approval in August.

The approval of radcivir is based on the results of three randomized controlled clinical trials involving patients hospitalized for covid-19 severity. A randomized, double-blind, placebo-controlled clinical trial conducted by the National Institute of allergy and infectious diseases evaluated the time taken for patients to recover from covid-19 within 29 days after treatment. The trial looked at 1062 hospitalized patients with mild, moderate and severe covid-19 who received either radcivir (541) or placebo (521) plus standard treatment. The median recovery time of covid-19 was 10 days in the radcivir group and 15 days in the placebo group, the difference was statistically significant. Overall, the probability of clinical improvement on day 15 was also statistically significantly higher in the radcivir group than in the placebo group.

Stephen Hahn, head of the FDA, said the approval was supported by a number of clinical trial data rigorously evaluated by the agency and represented an important scientific milestone in the new crown pandemic.

In an interview with Andrew Hill, a pharmacology researcher at the University of Liverpool, the Financial Times said the FDA had not included key data in its assessment. Rochelle walensky, director of infectious diseases at Massachusetts General Hospital and a professor at Harvard Medical School, said preliminary data on radcivirs benefits were sufficient to support the approval of radcivir, but added that it would be dishonest if Gilead knew about the solidarity test but did not include it in the submission.

Since the first outbreak of the new outbreak in China in December last year, scientists all over the world have embarked on the journey to find specific drugs.

The novel coronavirus pneumonia, novel coronavirus pneumonia, was reported in the January 31st issue of the new England Journal of medicine. The first successful case of the new crown pneumonia was reported in the United States. The patient received Reeds treatment at night. The clinical symptoms of other new crown pneumonia subsided in addition to a slow cough improvement. Reed English novel coronavirus pneumonia was called the hope of the people by the Chinese people. People hope it can lead the public out of the shadow of the new crown pneumonia.

On the domestic side, Professor Cao Bin, the first member of the national expert group and vice president of the China Japan Friendship Hospital, said in a live broadcast in March that he had targeted radcivir before he left Wuhan on January 9, which was still a nucleoside analogue developed by Gilead for antiviral treatment at that time.

In the novel coronavirus pneumonia, Cao Bin led two clinical trials of Reed in the field of mild or severe and severe new crown pneumonia in China. Two clinical trials were conducted in 10 hospitals in Wuhan, Hubei. However, the two clinical trials were terminated without the expected sample size due to the fall of domestic epidemic.

On April 29, the lancet, an international well-known medical journal, published the results of the clinical trial of radcivir conducted by the Chinese team. The results showed that no statistically significant clinical benefit was observed between the combination of radcivir and standard therapy.

Professor Cao Bin said at the time that the trial found that radcivir was safe and well tolerated, but had no significant benefit compared with placebo. On the same day, Gilead issued a statement saying that the National Institute of allergy and infectious diseases (NIAID) has obtained positive data on radcivir, we understand that the trial has reached the main endpoint, and NIAID will provide detailed information at the upcoming briefing.

In response to the different conclusions of the two experiments, Cao Bin said in an interview with surging in April that these are two different studies, and the evaluation criteria are different. at first, we imagined that radsiwei was a child of Tsinghua University and Peking University, but in fact, he could not go to school. His parents were too demanding on him. In an interview on April 29, Cao Bin said that Academician Wang Chen participated in the design and implementation of the experiment under the guidance of Academician Wang Chen. The experimental design was perfect, the most stringent standards were implemented in the research process, and the credibility of the experimental results was the highest. On August 6, Luo Yongqing, the former global vice president of Gilead science and general manager of China, said that Gilead is actively communicating with regulatory authorities, submitting rolling clinical trial data in time, and preparing for production, and will do its best to meet the needs of patients. However, at present, China has not yet approved the listing of redcivet, and Luo Yongqing also left Gilead on September 10. Source: interface news Author: Jin Miao, editor in charge: Wang Xiaowu_ NF

In response to the different conclusions of the two experiments, Cao Bin said in an interview with surging in April that these are two different studies, and the evaluation criteria are different. at first, we imagined that radsiwei was a child of Tsinghua University and Peking University, but in fact, he could not go to school. His parents were too demanding on him. In an interview on April 29, Cao Bin said that Academician Wang Chen participated in the design and implementation of the experiment under the guidance of Academician Wang Chen. The experimental design was perfect, the most stringent standards were implemented in the research process, and the credibility of the experimental results was the highest.

However, at present, China has not yet approved the listing of redcivet, and Luo Yongqing also left Gilead on September 10.